• Penumbra launched the FORWARD clinical study in distal acute ischemic stroke, enrolling its first patient in the trial.
• Prospective, real-world, multi-center study targets up to 250 patients across about 40 sites evaluating mechanical thrombectomy, including CAVT.
• Study will assess Penumbra’s RED reperfusion catheter portfolio, including THUNDERBOLT, for M2 occlusions versus medical management alone.
• THUNDERBOLT recently received CE Mark and FDA clearance, expanding Penumbra’s neuro thrombectomy offering with modulated aspiration technology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penumbra Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein.